may pharma tracker mix
may im drive stelara higher zytiga darzalex
estim lower forecast stabl pharma momentum
note compon pharma growth
import sentiment sustain
pharma perform largest correl stock perform
quarter compon matter well under-perform start
earli year driven initi conserv guidanc impli limit
pharma acceler remicad zytiga concern disappoint
actelion earli perform result beat estim pharma
organ growth q/q heavili depend zytiga contribut
pt growth face gener competit remicad weaker
declin exclud rebat actelion actual
slow factor drove under-perform quarter
despit beat pharma tracker leav us comfort overal
estim revenu mix import sentiment sustain
model remain larg unchang reflect stabil analysi
script drug price track lead us rais estim stelara
immunolog lower estim zytiga oncolog
darzalex oncolog overal continu
model organ growth pharma account gross net
adjust comp rel flattish indic estim
remicad defens strategi hold share price remain focu im
track suggest remicad continu hold share comfort
estim us y/i declin primarili driven
assumpt price concess defens strategi remicad consist
leverag broader pharma portfolio contract discuss
rebat make remicad cost competit cheaper biosimilar
interchang biosimilar us import given
remicad patient stabl brand product limit
visibl outcom septemb lawsuit recent
walgreen lawsuit alleg anti-competit practic
note manag commentari indic competit valu price
help stem biosimilar impact date beyond acknowledg risk
medic technolog unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
addit biosimilar entrant potenti litig uncertainti
estim alreadi reflect signific conservat annual declin
pipelin off-set remicad zytiga concern model organ
growth pharma harder compar zytiga go gener lead us
forecast pharma growth vs upsid come
pipelin key upcom catalyst like includ erleada
apalutamid uptak tremfya guselkumab uptak uptak exist
drug indic expans darzalex multipl myeloma transplant
inelig patient stelara crohn diseas indic expans
approv xarelto cad/pad esketamin file balanc
continu remicad eros zytiga face gener competit start
rebalanc diversifi busi profil improv multipl remain
equal-weight state divers three-way street believ less
balanc portfolio weigh multipl sit discount
 versu histor level busi perceiv like
pharma compani analyst day recent leadership chang indic
increas sens urgenc consum md turnaround
near term pharma perform strateg commentari drive
perform note tailwind includ pharma growth like
slightli better major pharma peer guidanc look achiev
modestli conserv potenti acceler consum think
higher pharma exposur warrant slightli greater discount
histor level maintain price target reflect
ep whether assum discount convers larg
come futur perform consum devic segment
note sandi peterson group world-wide chairman two busi
announc retir late june
recap signific pharma newsflow quarter signific pharma updat
quarter includ
esketamin data phase data esketamin nasal spray
patient treatment-resist depress fail respond two
antidepress treatment show statist signific
clinic meaning reduct depress symptom versu placebo
indic patient major depress fail respond
erdafitinib data phase data present show
confirm overal respons rate median progression-fre surviv
month patient metastat surgic unresect urotheli
cancer fgr alter given fda breakthrough therapi design
march plan move toward regulatori submiss phase
data continu pursu phase combo therapi
darzalex approv darzalex approv combin velcad
treatment patient newli diagnos patient multipl
myeloma transplant inelig follow phase alcyon
 biosimilar balanc pipelin balanc sheet margin expans
 biosimilar balanc pipelin balanc sheet margin expans
price target base base case
ep assum trade mid-singl digit discount
given slight discount versu in-lin histor multipl given
bull case ep
bull case ep
pharma pipelin exce expect due indic expans exist
franchis actelion surpass accret return target reinvest
pharma profit consum devic busi new commit return
addit sharehold buyback drive add ep
accret capit deploy drive upsid
base ep
base ep
revenu growth acceler remicad sale eros off-set
pipelin contribut improv devic consum actelion
acquisit integr time near term accret limit initi
 invest trade greater discount histor
bear ep
bear ep
revenu growth languish low singl digit amid deterior end
market remicad eros suffer aggress biosimilar price discount
addit entrant us market actelion integr fall track
md price pressur acceler multipl fall due structur
weaker revenu growth ineffici capit use long-term value-cr
pharma growth pipelin catalyst
off-set competit risk biosimilar
profil balanc improv segment
growth margin md consum
along margin expans initi
manag remain confid longer
term actelion accret growth
see potenti portfolio manag
expect divestitur ancillari slower
growth asset
pharma pipelin like take time
contribut near term risk
remicad biosimilar eros expect
margin initi remain track
increas bp year
manag also commit
reinvest upsid incom back
busi support growth
complet announc restructur
initi asset dispos
balanc sheet deploy
wacc return share repurchas
risk achiev price
anticip indic expans
exist pharma portfolio unabl off-set
investor concern around biosimilar
lower expect underli margin
expans benign price improv mix
wors expect fx headwind
greater expect price share
eros biosimilar across
exhibit sale ep
year year sale growth quarter date
quarter quarter sale growth quarter date
note us jv partnership cover ms
analyst david rising result pharmacycl acquisit book
us sale revenu profit share agreement place book net revenu
us imbruvica sale net residu profit earn sg reimburs
estim us imbruvica net revenu ou sale
imbruvica growth see increment benefit continu indic expans
effort includ recent fda approv relapsed/refractori margin zone
lymphoma said note acalabrutinib second-gener btk inhibitor
show better orr safeti cll patient ph studi may pose
longer term challeng compound current ph trial go
head head vs imbruvica core market high risk chronic lymphocyt leukemia
invokana daili type diabet treatment invokana first
inhibitor market follow astrazeneca farxiga recent boehringer/
lilli jardianc astrazeneca azn cover eu pharma team
cover ms analyst david rising note analysi group invokana
invokamet canagliflozin metformin farxiga xigduo dapagliflozin
market share perspect invokana continu see share loss
recent weekli data suggest share start
jardianc continu make inroad incumb
recent weekli read peg market share believ script track
indic jardianc cv benefit contribut share gain see cv
benefit class benefit benefit jardianc stand gain
rest plethora inhibitor market may also increas
potenti payer demand favor price use formulari
exclus pose anoth longer term threat note submit
snda invokana octob seek new indic reduc risk major
advers cardiovascular event mace base find canvas/canvs-r-
cv outcom approv expect year
estim us invokana sale ou sale
stelara continu add pharma franchis immunolog model us
stelara revenu expect us growth fall
growth stelara saw us see signific benefit gross-
to-net adjust recent im data trend encourag continu
cautiou around longer term prospect
stelara face competit core psoriasi indic drug includ
novarti nv cosentyx inhibitor well valeant brodalumab anoth il-
molecul also acknowledg recent ii result boehring
ingelheim compound similar safeti profil better efficaci
stelara note ms pharma analyst david rising announc
global collabor bi mab plaqu psoriasi compound
ixekizumab call taltz report higher respons rate vs stelara patient
moder sever plaqu psoriasi said note dermatologist tend
conserv stelara long safeti track record remain competit advantag
addit see effort indic expans stelara extend life-cycle
drug lupu adolesc moder sever plaqu psoriasi ulcer
xarelto continu leader anti-coagul market see eliqui
continu make gain said indic expans cad/pad
compass like contribut xarelto gain current model
us xarelto sale
im data week roll basi suggest xarelto held share sinc
last august note compass data set show signific prevent
major advers cardiac event patient coronari arteri diseas peripher
arteri diseas eliqui continu gain ground move xarelto share
script versu begin year
normal around share major zytiga share
increas last year current year date versu xtandi level
last seen mid bit surpris share shift perceiv xtandi
advantag term requir co-prescript steroid vs
zytiga zytiga gener manufactur current face month stay end
nce exclus limit entri late octob expect earlier
gener launch follow neg ipr rule see januari note detail
thought continu model gener competit current model
us ou revenu
